InvestmentApr 22, 2026, 12:12 AM
Maze Therapeutics Prices $150M Public Offering
AI Summary
Maze Therapeutics, Inc. announced the pricing of an underwritten registered offering, expecting to raise $150 million in gross proceeds. The offering includes 5,540,000 shares of common stock at $23.50 per share and up to 850,000 pre-funded warrants at $23.499 each. The company intends to use the net proceeds to advance research and development of its product candidates, MZE829 and MZE782, and for general corporate purposes, extending its operational runway into 2029.
Key Highlights
- Priced underwritten offering to raise $150 million in gross proceeds.
- Offering includes 5.54 million common shares at $23.50 per share.
- Also includes 0.85 million pre-funded warrants at $23.499 per warrant.
- Proceeds will fund R&D for MZE829 and MZE782 product candidates.
- Expected to fund operations into 2029 based on current business plan.